Aminoadamantane derivatives as therapeutic agents
CA 2400916 C · Owner: Neuromolecular, Inc. · Inventors: Ye, Wenqing; Stamler, Jonathan S.; Larrick, James W.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides novel aminoadamantane derivatives methods of , making the derivatives, compositions including the novel aminoadamantane derivatives, and methods for the treatment and prevention of neurological diseases using the derivatives and compositions. There are a variety of neurological disorders that can be treated using the present invention including, for example, the following: neurological disorders arising from trauma, ischemic or hypoxic conditions that can be treated include stroke hypoglycemia, cerebral ischemia, cardiac arrest spinal cord trauma, head , trauma, perinatal hypoxia cardiac arrest and hypoglycemic neuronal damage; neurodegenerative disorders …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 22, 2001 and granted July 10, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 22, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 22, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.